文献速递其他结缔组织病系统性红斑狼疮

在风险人群中预测自身免疫性结缔组织病:一种新型双评分系统对干扰素状态的预后价值

Prediction of autoimmune connective tissue disease in an at-risk cohort: prognostic value of a novel two-score system for interferon status.
PubMed 文献 · Ann Rheum Dis · 2018-06-21

前瞻性观察研究纳入118例完成12个月随访的自身免疫性结缔组织病风险个体,评估临床、干扰素及影像学预测因子;19/118(16%)进展为自身免疫性结缔组织病(系统性红斑狼疮14例、原发性干燥综合征5例)。多变量分析中仅自身免疫性风湿病家族史(OR 8.2,95%CI 1.58至42.53)与IFN-Score-B(3.79,95%CI 1.50至9.58)增加进展风险。作者认为双因子干扰素评分与家族史可预测从抗核抗体阳性进展为自身免疫性结缔组织病。

要点

  • 118例风险个体随访12个月,19/118(16%)进展为自身免疫性结缔组织病(系统性红斑狼疮14例、原发性干燥综合征5例)。
  • 进展者基线IFN-Score-B的倍数差异为3.22(95%CI 1.74至5.95,p<0.001),IFN-Score-A为2.94(95%CI 1.14至7.54,p=0.018)。
  • 多变量logistic回归中仅自身免疫性风湿病家族史(OR 8.2,95%CI 1.58至42.53)与IFN-Score-B(3.79,95%CI 1.50至9.58)增加进展风险。

核心结论

  • 双因子干扰素评分与家族史可预测从抗核抗体阳性进展为自身免疫性结缔组织病。
  • 作者认为这些干扰素评分或可对自身免疫性结缔组织病风险个体进行分层,从而为疾病预防的早期干预及避免不可逆器官损伤提供可能。

研究设计与样本

  • 前瞻性观察研究,纳入自身免疫性结缔组织病风险个体(定义为抗核抗体阳性、≤1项系统性红斑狼疮临床标准、症状持续时间<12个月且未治疗)。
  • 检测血液与非皮损皮肤活检中两种既往描述的干扰素刺激基因表达评分(IFN-Score-A与IFN-Score-B),并以49例健康对照与114例系统性红斑狼疮分别作为阴性对照与阳性对照。
  • 进行肌肉骨骼超声检查,进展定义为12个月时满足自身免疫性结缔组织病分类标准。

主要发现

  • 118例完成12个月随访的个体中,19/118(16%)进展为自身免疫性结缔组织病(系统性红斑狼疮14例、原发性干燥综合征5例)。
  • 基线时风险组、健康对照组与系统性红斑狼疮组的两种干扰素评分均存在差异(p<0.001)。
  • 12个月时进展为自身免疫性结缔组织病的风险个体基线两种干扰素评分均高于未进展者,IFN-Score-B的倍数差异为3.22(95%CI 1.74至5.95,p<0.001),大于IFN-Score-A的2.94(95%CI 1.14至7.54,p=0.018)。
  • 进展者基线临床特征或超声所见未显著高于未进展者。
  • 风险组与健康对照组之间IFN-Score-A的倍数差异在皮肤中明显大于血液。

关键数值与推荐

  • 进展定义为12个月时满足自身免疫性结缔组织病分类标准。
  • 风险个体定义:抗核抗体阳性、≤1项系统性红斑狼疮临床标准、症状持续时间<12个月且未治疗。
  • IFN-Score-B的倍数差异为3.22(95%CI 1.74至5.95,p<0.001),IFN-Score-A为2.94(95%CI 1.14至7.54,p=0.018),均为进展者与非进展者比较。
  • 多变量分析中自身免疫性风湿病家族史OR 8.2(95%CI 1.58至42.53),IFN-Score-B OR 3.79(95%CI 1.50至9.58)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate clinical, interferon and imaging predictors of progression from 'At Risk' to autoimmune connective tissue diseases (AI-CTDs). METHODS: A prospective observational study was conducted in At-Risk of AI-CTD (defined as antinuclear antibody (ANA) positive; ≤1 clinical systemic lupus erythematosus (SLE) criterion; symptom duration <12 months and treatment-naïve). Bloods and skin biopsy (non-lesional) were analysed for two interferon-stimulated gene expression scores previously described (IFN-Score-A and IFN-Score-B). Forty-nine healthy controls (HCs) and 114 SLE were used as negative and positive controls. Musculoskeletal ultrasound was performed. Progression was defined by meeting classification criteria for AI-CTDs at 12 months. RESULTS: 118 individuals with 12-month follow-up were included. Of these, 19/118 (16%) progressed to AI-CTD (SLE=14, primary Sjogren's=5). At baseline, both IFN scores differed among At-Risk, HCs and SLE groups (p<0.001) and both were elevated in At-Risk who progressed to AI-CTD at 12 months versus non-progressors, to a greater extent for IFN-Score-B (fold difference (95% CI) 3.22 (1.74 to 5.95), p<0.001) than IFN-Score-A (2.94 (1.14 to 7.54); p=0.018). Progressors did not have significantly greater baseline clinical characteristics or ultrasound findings. Fold difference between At-Risk and HCs for IFN-Score-A was markedly greater in skin than blood. In multivariable logistic regression, only family history of autoimmune rheumatic disease, OR 8.2 (95% CI 1.58 to 42.53) and IFN-Score-B, 3.79 (1.50-9.58) increased the odds of progression. CONCLUSION: A two-factor interferon score and family history predict progression from ANA positivity to AI-CTD. These interferon scores may allow stratification of individuals At-Risk of AI-CTD permitting early intervention for disease prevention and avoid irreversible organ damage.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Md Yusof MY, Psarras A, El-Sherbiny YM, et al. Prediction of autoimmune connective tissue disease in an at-risk cohort: prognostic value of a novel two-score system for interferon status. Ann Rheum Dis. 2018. PMID: 29929956. doi:10.1136/annrheumdis-2018-213386

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。